NCT07067359Not yet recruiting
The Intensive Nutritional Support in Esophageal Cancer Undergoing Neoadjuvant Therapy
Effect of Intensive Nutrition Intervention in Esophagogastric Cancer Patients With Neoadjuvant Therapy: A Randomized Clinical Trial
Source: ClinicalTrials.gov · Last updated 16 Jul 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Patients with esophageal cancer undergoing neoadjuvant therapy were selected as research subjects for nutritional risk screening and malnutrition assessment. Patients identified with nutritional risk were randomized into the standard nutrition therapy group (SNT) and the intensive nutrition therapy group (INT). The surgical rate was evaluated in both groups of patients, and the effects of nutritional support therapy on nutritional status and quality of life were investigated.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- First submitted
- 23 Jan 2025
- Start date
- 15 Jul 2025
- Primary completion date
- 30 Dec 2025
- Lead sponsor
- Sichuan University
- Diseases
- Gastric and esophageal cancer
- NCT number
- NCT07067359
What you commit to
- Study type: Interventional
- Planned participants: 200
- From 15 Jul 2025 to the primary completion date, 30 Dec 2025
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Other tumors, including pancreatic cancer, liver cancer and other solid digestive tract tumors, colon cancer, rectal cancer and other tubular lower digestive tract tumors;
- Have serious heart, lung and brain diseases;
- Patients with unstable vital signs and multiple organ failure;
- The investigator believes that the subjects have a history of other serious systemic diseases or are not suitable for participating in this clinical study for other reasons
Other
- The patient has poor cognitive ability and is unable to answer questions or fill out questionnaires;
- Eastern Cooperative Oncology Group score \>2;
Who the study is looking for
- Esophageal cancer；
- Patients were staged as cT1b-cT2N+M0 or cT3-cT4a, any N, M0. Based on the location of the tumor and clinical staging, they were defined as locally advanced resectable esophageal cancer；
- Patients planned for neoadjuvant therapy, with radical surgical resection intended after neoadjuvant treatment；
- Normal gastrointestinal function；
- PG-SGA score \>3;
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤2分.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.